# Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia

> **NCT01452646** · PHASE2 · COMPLETED · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 515 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **OTHER:** Risk-adapted, MRD-directed therapy

## Key facts

- **NCT ID:** NCT01452646
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2017-07
- **Final completion:** 2018-07-10
- **Target enrollment:** 515 (ESTIMATED)
- **Last updated:** 2018-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01452646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01452646, "Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01452646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*